Incyte

INCY

----

Current ValuationThe current P/E ratio is 14.17, below the reasonable range, cheaper than 95.01% of the time in the past 3 years, and the industry ranks 34/602, the industry Median -2.08.

14.17xP/E

Stock price$112.73Earnings per share$7.95

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.

019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.

0x30x60x90x120x150x

P/E ratio
Name/Symbol
INCYUSIncyte	14.17x	68.35%	$22.85B
GRFSUSGRIFOLS SA	9.85x	42.44%	$5.17B
ACADUSAcadia Pharma	8.94x	73.45%	$3.40B
PURRUSHyperliquid Strategies	9.65x	67.60%	$2.47B
ADMAUSAdma Biologics	13.50x	35.42%	$2.28B
AUPHUSAurinia Pharma	6.65x	54.40%	$2.09B
LKFTUSLakefront Biotherapeutics	2.75x	86.19%	$1.91B
ANABUSAnaptysbio	5.46x	1,003.56%	$1.43B
VORUSVor BioPharma	1.73x	89.77%	$1.08B
MGTXUSMeiraGTx	12.89x	122.03%	$1.02B
ABUSUSArbutus Pharma	5.76x	533.09%	$882.29M
RIGLUSRigel Pharma	2.68x	83.91%	$861.33M
BVNRYUSBavarian Nordic A/S	3.50x	--	$839.97M
IRWDUSIronwood Pharma	4.62x	715.55%	$599.82M
AGENUSAgenus	3.67x	--	$337.20M
CUVLUSClinuvel Pharmaceuticals	12.47x	--	$285.93M
QTTBUSQ32 Bio	7.15x	162.67%	$241.43M
PLXUSProtalix Biotherap	11.61x	400.00%	$219.96M
CGENUSCompugen	5.98x	173.68%	$210.29M
VXRTUSVaxart	2.75x	328.57%	$106.10M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.